Best Practice and Research. Clinical Haematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

CAR T cells, immunologic and cellular therapies in hematologic malignancies
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Renier Brentjens, Marco L. Davila (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Leena Halim, Adam Ajina, John MaherAbstractFollowing the landmark approvals by the United States Food and Drug Administration, the adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells has now entered mainstream clinical practice for patients with chemotherapy-resistant or refractory B-cell malignancies. These approvals have followed on from a prolonged period of pre-clinical evaluation, informing the design of clinical trials that have demonstrated unprecedented efficacy in this difficult to ...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

GMP CAR-T cell production
This article reviews the issues that must be addressed in order to achieve this goal. It includes the manufacturing infrastructure, the regulatory environment, practical aspects of production, and the costs involved. (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

CAR T cell therapy for B-cell lymphomas
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Julio C. Chavez, Frederick L. LockeAbstractB-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited ...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

The unique biology and treatment of primary mediastinal B-cell lymphoma
Publication date: Available online 3 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Alessandro Broccoli, Pier Luigi ZinzaniAbstractThe unique biological features of primary mediastinal large B-cell lymphoma are offering suggestions for the development and application of innovative drugs in patients who do not respond to first-line regimens or relapse. This lymphoma, in fact, is characterised by high rates of curability with standard anthracycline-containing chemoimmunotherapy regimens, but still displays a severe prognosis if adequate responses are not rapidly achieved or if the disease recurs. Ra...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Extranodal NK/T-cell lymphoma: updates in biology and management strategies
Publication date: Available online 3 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Motoko Yamaguchi, Masahiko Oguchi, Ritsuro SuzukiAbstractExtranodal NK/T-cell lymphoma, nasal type (ENKL), is a rare lymphoma subtype of peripheral T/NK-cell lymphoma that is very common in East Asia and Latin America. Two-thirds of patients have localized disease in the nasal cavity or adjacent sites. Large retrospective studies have revealed the clinicopathologic features of ENKL patients, identified risk factors for short survival time, and developed prognostic models. Next-generation sequencing studies have pro...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Monitoring Clinical Outcomes in Aggressive B-cell Lymphoma: From Imaging Studies to Circulating Tumor DNA
Publication date: Available online 3 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Christopher Melani, Wyndham H. Wilson, Mark RoschewskiAbstractRecent guidelines have de-emphasized the role of routine surveillance computed tomography (CT) scans for diffuse large B-cell lymphoma (DLBCL) patients who achieve a complete response to front-line therapy. This shift in practice recommendations was prompted by retrospective studies that failed to demonstrate clear clinical utility for surveillance CT in unselected DLBCL patients. Controversy remains, however, over the role of routine surveillance CT in ...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Evolving treatment strategies in mantle cell lymphoma
Publication date: Available online 7 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Natasha Catherine Edwin, Brad KahlAbstractMantle cell lymphoma is an incurable, moderately aggressive B cell lymphoma. While a small proportion of patients with indolent disease can be managed expectantly, most patients require treatment. The therapeutic approach is driven by physician recommendation, patient choice, age, fitness and comorbidities. Young, fit patients often receive combination chemoimmunotherapy, including high dose cytarabine, with autologous stem cell transplant. Recent data has indicated benefit...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Dissecting aggressive B-cell lymphoma through genomic analysis – What is clinically relevant?
Publication date: Available online 7 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): David W. Scott, Lisa M. RimszaAbstractThe aggressive B-cell lymphomas are a diverse collection of cancers grouped together based on clinical behavior and derivation from B lymphocytes. Genomic analyses on these tumours are now translating into improved classification systems and identification of underpinning targetable biology. Simple karyotyping revealed key translocations involving MYC, BCL2, and BCL6 that have impacted lymphoma classification in the World Health Organization classification scheme. Subsequently,...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Evolving treatment strategies in mantle cell lymphoma
Publication date: Available online 7 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Natasha Catherine Edwin, Brad KahlAbstractMantle cell lymphoma is an incurable, moderately aggressive B cell lymphoma. While a small proportion of patients with indolent disease can be managed expectantly, most patients require treatment. The therapeutic approach is driven by physician recommendation, patient choice, age, fitness and comorbidities. Young, fit patients often receive combination chemoimmunotherapy, including high dose cytarabine, with autologous stem cell transplant. Recent data has indicated benefit...
Source: Best Practice and Research Clinical Haematology - July 8, 2018 Category: Hematology Source Type: research

Dissecting aggressive B-cell lymphoma through genomic analysis – What is clinically relevant?
Publication date: Available online 7 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): David W. Scott, Lisa M. RimszaAbstractThe aggressive B-cell lymphomas are a diverse collection of cancers grouped together based on clinical behavior and derivation from B lymphocytes. Genomic analyses on these tumours are now translating into improved classification systems and identification of underpinning targetable biology. Simple karyotyping revealed key translocations involving MYC, BCL2, and BCL6 that have impacted lymphoma classification in the World Health Organization classification scheme. Subsequently,...
Source: Best Practice and Research Clinical Haematology - July 7, 2018 Category: Hematology Source Type: research

What is the optimal management of older CLL patients?
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Jennifer A. WoyachAbstractCLL is the most common leukemia in older adults with a median age at diagnosis of 71. Therefore, management of patients with this disease must take into account the older age of most patients and consequences of this in terms of functional status and organ function. This review will discuss the management of CLL with regards to observation prior to the initiation of therapy, functional status, and initial treatment. We will discuss criteria for the initiation of therapy, and how initial ...
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research

Index
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research

Novel therapies for relapsed/refractory mantle cell lymphoma
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Puja C. Arora, Craig A. PortellAbstractMantle cell lymphoma is an aggressive Non-Hodgkin's lymphoma that is considered incurable with standard therapies. Most patients treated with frontline immunochemotherapy relapse within a few years and do not usually respond to salvage chemotherapy. Persistent activation of the B-cell receptor pathway is critical to the pathogenesis of mantle cell lymphoma. Inhibition of Bruton's tyrosine kinase, an essential B-cell receptor pathway component with ibrutinib has shown clinica...
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research

Editorial Board / Aims & Scope
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research